Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xenon
Biotech
Xenon's MDD med fails ph. 2, elevating seizure potential
Xenon's lead asset failed a trial in patients with major depressive disorder, though executives remained bullish on the med's epilepsy potential.
Max Bayer
Nov 27, 2023 10:45am
Double whammy for Neurocrine as Takeda, Xenon pacts fail
Nov 10, 2023 7:22am
Biohaven veers toward Kv7 platform following Pfizer sale
Oct 4, 2022 11:48am
Xenon frees itself of some XEN1101 milestone obligations
Sep 11, 2018 9:55am
Xenon adds discontinued GSK drug to epilepsy pipeline
Sep 6, 2018 10:20am
Xenon’s epilepsy drug clears phase 1b
Aug 29, 2018 9:50am
